JEIL PHARMACEUTICAL CO., LTD.
🇰🇷South Korea
Clinical Trials
35
Active:0
Completed:28
Trial Phases
5 Phases
Phase 1:21
Phase 2:3
Phase 3:6
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (33 trials with phase data)• Click on a phase to view related trials
Phase 1
21 (63.6%)Phase 3
6 (18.2%)Phase 2
3 (9.1%)Not Applicable
2 (6.1%)Phase 4
1 (3.0%)Observationa Study is a Prospective and Multi-institutional Observational Study.
Completed
- Conditions
- Erosive Reflux DiseaseHeartburnAcid Regurgitation
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 5536
- Registration Number
- NCT06952855
- Locations
- 🇰🇷
Goodbreath Medical Center, Seoul, Gyeonggi-do, Korea, Republic of
To Evaluate the Safety, Pharmacokinetic Characteristics and the Effect of Food After Administration of JLP-2004
Phase 1
Recruiting
- Conditions
- Healthy
- Interventions
- Drug: JLP-2004 qd
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06431399
- Locations
- 🇰🇷
Chungbuk National University Hospital, Chungju, Seowon-gu, Korea, Republic of
To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JC-001 and JLP-1901
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06171880
- Locations
- 🇰🇷
Bundang CHA university global clinical trials center Institutional Review Board, Gyeonggi-do, Bundang-gu, Korea, Republic of
To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06169059
- Locations
- 🇰🇷
H plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008
Phase 1
Completed
- Conditions
- Healthy Adult
- Interventions
- Drug: SGLT2 inhibitor
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06165965
- Locations
- 🇰🇷
Bundang CHA university global clinical trials center Institutional Review Board, Gyeonggi-do, Bundang-gu, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
No news found